Nevan Krogan - A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug RepurposingSpeaker
Tiannan Guo - Proteomic Characterization of COVID-19 Patient SeraSpeaker
Thank you for attending this webinar on July 21, 2020, at 14:00 UTC. To access the recording of this webinar, please visit: On-Demand Library
This webinar was moderated by Perdita Barran and expanded into two presentations with two featured speakers.
A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug Repurposing - Nevan Krogan
Proteomic Characterization of COVID-19 Patient Sera - Tiannan Guo
Professor Barran holds a Chair of Mass Spectrometry in the School of Chemistry and is Director of the Michael Barber Centre for Collaborative Mass Spectrometry at the Manchester Institute of Biotechnology, The University of Manchester, UK. From 2002-2013 she was at the University of Edinburgh as an EPSRC Advanced Research Fellow, Senior Lecturer and then Reader in Biophysical Chemistry. She graduated from Manchester University with a degree in Chemistry with Industrial Experience (1994), and from Sussex University with a PhD in Chemical Physics (1998) under the supervision of Professors Tony Stace and Sir Harry Kroto. She worked as a post-doctoral researcher for Tony Stace, before moving to the University of California Santa Barbara to work with Mike Bowers. Her research interests include: Biological mass spectrometry; Instrument and technique development; Protein structure and interactions; Dynamic and Disordered Systems; Parkinson’s disease Diagnostics; HDX-MS; Proteomics; and Molecular modeling. She is a Fellow of the Royal Society of Chemistry and was awarded the Theophilius Redwood Award from the RSC in 2019, Researcher of the Year 2020 from the University of Manchester and the ACS Measurement Science Lectureship 2021. Perdita has authored over 140 publications in peer reviewed journals which have been cited over 4000 times, by people other than her.
Nevan Krogan, PhD, is a molecular biologist, UC San Francisco professor, and director of the intensely interdisciplinary Quantitative Biosciences Institute (QBI) under the UCSF School of Pharmacy. He is also a senior investigator at the Gladstone Institutes.
He led the work to create the SARS-CoV-2 interactome and assembled the QBI Coronavirus Research Group (QCRG), which includes hundreds of scientists from around the world. His research focuses on developing and using unbiased, quantitative systems approaches to study a wide variety of diseases with the ultimate goal of developing new therapeutics.
Nevan serves as Director of The HARC Center, an NIH-funded collaborative group that focuses on the structural characterization of HIV-human protein complexes. Dr. Krogan is also the co-Director of three Cell Mapping initiatives, the Cancer Cell Mapping Initiative (CCMI), the Host Pathogen Map Initiative (HPMI) and the Psychiatric Cell Map Initiative (PCMI). These initiatives map the gene and protein networks in healthy and diseased cells with these maps being used to better understand disease and provide novel therapies to fight them.
He has authored over 250 papers in the fields of genetics and molecular biology and has given over 250 lectures and seminars around the world. He is a Searle Scholar, a Keck Distinguished Scholar and was recently awarded the Roddenberry Prize for Biomedical Research.
Tiannan Guo received training of clinical medicine in Tongji Medical College, Huazhong University of Science and Technology (1999-2006), and biology in Wuhan University (2001-2005), before he moved to Singapore for PhD training in cancer proteomics in the laboratories of Dr. Newman Sze in Nanyang Technological University and Dr.Oi Lian Kon in National Cancer Centre Singapore (2008-2012). In 2012, Tiannan started his postdoctoral training in the laboratory of Dr. Ruedi Aebersold in ETH Zurich. In March 2017, Tiannan relocated to ProCan, Children’s Medical Research Institute, The University of Sydney as the Scientific Director. Since August 2017, he became a Tenure Track Assistant Professor in Westlake University, Hangzhou, China. The Guo lab (www.guomics.com) focuses on advancing proteomics technologies for clinical cohort studies.
To view this presentation, please login with your HUPO Connect Webinar Series login credentials. If you do not have an account or access to this presentation, please click here to register an account.